Showing 541-550 of 7435 results for "".
Antibiotics and the Mutant Selection Window
https://practicaldermatology.com/topics/atopic-dermatitis/antibiotics-and-the-mutant-protection-window/19537/When considering antibiotics for treating acne, Hilary Baldwin, MD says there's a new concept dermatologists should consider in preventing antibiotic resistance. She describes the mutant selection window and why a higher dose antibiotic may actually be safer and more effective.2017 Tax Cuts and Jobs Act: What You Need to Know
https://practicaldermatology.com/topics/practice-management/2017-tax-cuts-and-jobs-act-what-you-need-to-know--vmyiwowa/18348/OJM Group principal Carole Foos, CPA provides an overview of the Tax Cuts and Jobs Act, which was signed in to law at the end of 2017. She discusses key provisions affecting individual physicians and medical practices, and offers advice to consider when planning for 2018 and beyond. Click here to reImproving Therapeutic Outcomes for Acne Patients Using Topical Medications
https://practicaldermatology.com/topics/practice-management/improving-therapeutic-outcomes-for-acne-patients-using-topical-medications/20403/Four pearls for making today's acne therapies work for your patients.Allergan Acquires Vitae, PsA Day, Novan News
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-allergan-acquires-vitae-psa-day-novan-news/18572/Allergan is acquiring clinical-stage biotechnology company Vitae Pharmaceuticals for $21.00 per share, in cash, for a total transaction value of approximately $639 million. Novan has launched its initial public offering and is now listed on the NASDAQ. Celgene Corporation and the National PsoriasisWhat's New in Topical Acne Therapy
https://practicaldermatology.com/topics/practice-management/whats-new-in-topical-acne-therapy/21105/From new approvals to a growing pipeline, the outlook is bright for the continued refinement of topical acne therapy.Restylane Lyft Approved, Analyzing New Quality of Life Data
https://practicaldermatology.com/series/dermwire-tv/dermwire-restylane-lyft-approved-analyzing-new-quality-of-life-data--ibalorid/18878/Restylane Lyft from Galderma approved for mid face volume enhancement, New data analyzes significance of patient quality of life in diseases like psoriasis and atopic dermatitis, Merz North America establishes new headquarters in Raleigh, NC, and Boston unveils free sunscreen dispensers.Radiesse for Hands, Alevicyn Cleared
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-radiesse-for-hands-alevicyn-cleared/18898/Merz gets FDA approval for Radiesse for hand augmentation and releases data comparing Xeomin to Botox. Heidi Waldorf, MD, FAAD and Michael Gold, MD, FAAD, comment. Also in this edition, Galderma participate in a White House forum on antibiotic stewardship, and the FDA gives 510(k) clearance to AleviDos and don'ts for creating a killer Google Adwords Campaign for your Dermatology Practice
https://practicaldermatology.com/topics/practice-management/dos-and-don-ts-for-creating-a-killer-google-adwords-campaign-for-your-dermatology-practice/18907/Google AdWords could be a great way to promote your practice. But you have to do it right! Learn how to plan and implement a campaign that gets results with reasonable costs.Kythera's Kybella Approved; ASLMS Update
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-kythera-s-kybella-approved-aslms-update/18925/FDA Approves Kythera's Kybella (ATX-101 or deoxycholic acid) injection for reduction of sub mental fullness or double chin. ASLMS Recognizes women in device-based medicine (Women in Energy-based Devices). Deka and Syneron get new clearances. ASDS Launches Skin Cancer PSAs, and Foamix sells shares.Beware of Your CPA's Advice on Asset Protection
https://practicaldermatology.com/topics/practice-management/beware-of-your-cpas-advice-on-asset-protection/21234/The advice you get may be inaccurate.